microport® endovascular attended the fifth shandong (mount tai) aortic surgery forum2017-云顶国际

jinan, china – on march 10, microport endovascular (shanghai) co., ltd. ("microport® endovascular") attended the fifth shandong (mount tai) aortic surgery forum in jinan, shandong province. the forum was mainly hosted by the vascular surgery branch of shandong medical doctor association and the vascular surgery branch of shandong medical association, and organized by shandong provincial hospital.

focused on the lasted advancement and discipline construction of aortic surgery disease treatment, the forum invited many domestic and international experts to have in-depth discussions on hot topics of the vascular surgery industry. professor weiliang jiang of the second affiliated hospital of harbin medical university shared the method and therapeutic evaluation of branch reconstruction on aortic arch, and compared the three techniques "chimney," "fenestration" and "branched stent" in terms of operating method, clinical efficacy, and long-term complications. during his speech, professor jiang presented several cases in which microport® endovascular in-house developed castor™ branched aortic stent graft and delivery system ("castor™") was used, and commented: "castor™ enlarges the indication of tevar surgery, lowered the occurrence of endoleaks, and has excellent safety and efficacy. it is the endovascular branched stent graft system that may successfully deal with the problem of aortic arch."

castor™ is the world's first branched stent graft system designed for an entirely endovascular treatment of thoracic dissection encroaching the left subclavian artery or the original tear located within 15mm distal to the left subclavian artery. castor™ employs an easy-to-use unibody design, including a main body and a branch stent graft for the left subclavian artery as a whole. in 2015, castor™ was granted the green-path by the china food and drug administration ("cfda"), a special fast-track procedure for innovative medical devices to gain cfda approval, and is expected to gain the cfda approval within this year to officially enter the china market.

during the forum, microport® endovascular displayed several innovative products such as hercules™-t low profile stent-graft and delivery system and aegis™ bifurcated stent-graft system and delivery system, and provided product simulators for attendees to get the hands-on experience with the features and operating techniques of microport® endovascular products. in the future, microport® endovascular will continue to stick to the innovative r&d and broaden its product line, to offer individualized treatment and service to patients with aortic and peripheral vascular diseases.